Johnson & Johnson and McKesson make a big splash in merger and acquisition activity, courts block Humana/Aetna merger and Allergan and Endo sued by FTC. The healthcare cohort has witnessed several key events in the face of a political backdrop that’s put the entire industry on edge. The overall healthcare umbrella has become sensitive to any tweet from President Trump as he vows to bring down drug prices. As he pursues his crusade against drug pricing, much of these threats may have already been priced-in as seen in many healthcare-related stocks (i.e. McKesson, CVS, ABBV and AGN) that have seen sharp and sustained sell-offs that coincide with the 2017 presidential campaign cycle.
Hello MarketClub members everywhere. Stocks are fluctuating near all-time highs as investors weigh the prospects for further gains after mixed corporate earnings from companies including Netflix Inc. (NASDAQ:NFLX), Johnson & Johnson (NYSE:JNJ) and The Goldman Sachs Group Inc.(NYSE:GS).
There's a good reason that investors love high yielding dividend stocks. Not only does a dividend help buffer against downside risk, it also provides a steady base of returns over time that compounded, can add up to higher growth than you might expect.
Usually investors think of dividend paying stocks as large behemoths that simply don't have the ability to grow like it's smaller, younger competitors. It's a myth that's led many investors away from solid opportunities. These large entities might grow at a slower rate than you want, but when you factor in the dividends and the small downside risk these companies tend to have, you could find an investment that matches any high-risk small cap growth stock without having to expose yourself to unnecessary risk.
For a good example, all we need to do is look at Johnson & Johnson's (JNJ) stock.
As America ages, healthcare is going to be an important issue. How companies approach this is going to make a big difference to their bottom line.
The new Affordable Care Act, which is slowly being implemented, is another dimension that will have to be factored into the future. How companies adapt and make money in the future may have more to do with how they do business, rather than the drugs they are pushing.
Today, I'll be looking at four stocks, two that are in strong bullish trends according to the Trade Triangle technology, and two that are in downtrends.
From the long side based on the Trade Triangle technology:
Abbott Laboratories (NYSE:ABT)
Johnson & Johnson (NYSE:JNJ)